All In Biotech

Drug Trial Radar · NCT04752722

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Apr 22, 2021

Primary completion

Apr 30, 2028

Study completion Oct 30, 2030

Sponsor

Lead sponsor
enGene, Inc.Industry
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC. A Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.

Conditions

  • Superficial Bladder Cancer
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
  • Non-muscle Invasive Bladder Cancer

Interventions

  • EG-70 (phase 1)Drug

    Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.

  • EG-70 (phase 2) Master ProtocolDrug

    Under the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles, of EG-70 at the RP2D defined in Phase 1, administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.

  • Surfactant Bladder Pre-Rinse and EG-70 (Substudy)Drug

    Patients will receive via catheter a 50 mL volume of a 5-minute bladder rinse immediately prior to administration of 50 mL of detalimogene voraplasmid (EG-70) at the RP2D for 30 minutes. During the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles of the sudy intervention. One cycle lasts approximately 12 weeks. For Maintenance treatment, 2 doses of the study intervention will be administered as a bladder instillation per 12-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0.Time frame: Approximately 2 years
  2. Phase 2: Percentage of patients with cystoscopic CR at any time, based on exam, urine cytology and appropriate biopsies.Time frame: Approximately 24 weeks
  3. Phase 2: Nature, incidence, relatedness, and severity of treatment emergent adverse events (as assessed by CTCAE v5.0)Time frame: Approximately 3 years

Locations

102 sites in 10 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham Clinical Research Unit (CRU)

    Birmingham, Alabama · Recruiting

  • Mayo Clinic

    Scottsdale, Arizona · Recruiting

  • Urological Associates of South Arizona

    Tucson, Arizona · Completed

  • Arkansas Urology

    Little Rock, Arkansas · Recruiting

  • University of California - Irvine Medical Center

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Tower Urology

    Los Angeles, California · Recruiting

  • Om Research

    San Diego, California · Recruiting

  • Colorado Clinical Research

    Lakewood, Colorado · Recruiting

  • The George Washington Medical Faculty Associates

    Washington D.C., District of Columbia · Recruiting

  • University of Florida

    Jacksonville, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Urology of Indiana

    Greenwood, Indiana · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • John Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Chesapeake Urology Research Associates

    Hanover, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Corewell Health Medical Group and Spectrum Health Hospitals

    Grand Rapids, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • New Jersey Urology, LLC

    Voorhees Township, New Jersey · Recruiting

  • Albany Medical College

    Albany, New York · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Mount Sinai Medical Center

    New Haven, New York · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Completed

  • Associated Medical Professionals of NY,

    Syracuse, New York · Recruiting

  • UNC Chapel Hill Hospital

    Chapel Hill, North Carolina · Recruiting

  • Duke Health - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Associated Urologists of North Carolina

    Raleigh, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Central Ohio Urology Group

    Gahanna, Ohio · Recruiting

  • Clinical Research Solutions - Helios Clinical Research

    Middleburg Heights, Ohio · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Carolina Urologic Research Center, LLC

    Myrtle Beach, South Carolina · Recruiting

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.